Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L6XG
|
|||
| Drug Name |
Carbamate derivative 9
|
|||
| Synonyms |
PMID29053063-Compound-10a
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
PFIZER INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H23F3N2O6S
|
|||
| Canonical SMILES |
C1CN(CCC12CC(CO2)NS(=O)(=O)C3=CC=CC=C3)C(=O)OC(CO)C(F)(F)F
|
|||
| InChI |
1S/C18H23F3N2O6S/c19-18(20,21)15(11-24)29-16(25)23-8-6-17(7-9-23)10-13(12-28-17)22-30(26,27)14-4-2-1-3-5-14/h1-5,13,15,22,24H,6-12H2/t13-,15-/m1/s1
|
|||
| InChIKey |
KBPUJKKMMQDFKB-UKRRQHHQSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| Monoglyceride lipase (MAGL) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fatty acid amide hydrolase (FAAH) | Target's Patent Info | [1] | |
| Monoglyceride lipase (MAGL) | Target's Patent Info | [1] | ||
| BioCyc | Anandamide degradation | |||
| Triacylglycerol degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Panther Pathway | Anandamide degradation | |||
| Reactome | Acyl chain remodeling of DAG and TAG | |||
| Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | ||||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| Glycerophospholipid biosynthesis | ||||
| GPCR downstream signaling | ||||
| Effects of PIP2 hydrolysis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.